The role of monoamine oxidase B inhibitor rasagiline in the treatment of Parkinson’s disease

A.V. Demchenko


The article discusses the problem of Parkinson’s disease (PD), which is the second most important neurodegenerative disease in developed society after Alzheimer’s disease. In Ukraine, the prevalence of PD is 140 cases per 100,000 population. The main factors that increase the mortality rate in PD are dementia, the presence of hallucinations, dysphagia, the predominance of akinetic and rigid form with early impaired balance and gait. Absence of classical resting tremor, symmetry of symptoms are associated with decreased survival, while the presence of resting tremor — with its increase. The main problem in the treatment of PD is that, despite significant improvement in the quality of life of patients and pronounced symptomatic effect, in general, modern therapeutic options do not yet allow preventing further degeneration of dopaminergic neurons and disease progression. Therefore, clinical practice requires therapy influencing the pathogenetic basis of the disease. This is especially important when patients in the early stages of PD have the highest neuroplastic reserve, and the strategy for their continuous treatment should be oriented for decades to come. The development of new therapeutics, including selective monoamine oxidase (MAO) inhibitors, has changed the “face” of PD treatment. Patients aged 50–70 years with low and moderate motor deficits and without significant cognitive impairment receive treatment with MAO-B inhibitor or dopamine receptor agonists, in severe motor disorders — with levodopa preparations, and when its small doses (300–400 mg/day) do not provide sufficient clinical effect, MAO-B inhibitor, dopamine receptor agonists or amantadine are prescribed additionally to avoid further increase in levodopa dose. Adding MAO-B inhibitor and/or dopamine receptor agonists to levodopa makes it possible to reduce its dose by 15–30 % without loss of effectiveness and helps delay the development of motor fluctuations.


Parkinson’s disease; treatment; selective monoamine oxidase inhibitors


Амосова Н.А., Смоленцева И.Г., Маслюк О.А. Анализ причин смерти у больных болезнью Паркинсона. Журнал неврологии и психиатрии. 2017. № 6. Вып. 2. С. 70-72.

Богданов Р.Р., Турбина Л.Г., Котов С.В. Опыт применения препарата Азилект (разагилин) в лечение больных с начальными проявлениями болезни Паркинсона. Эффективная фармакотерапия. Неврология и психиатрия. 2012. № 1. С. 2-6.

Евтушенко С.К. Современные вопросы диагностики и фармакотерапии болезни Паркинсона и ее фенокопий. Міжнародний неврологічний журнал. 2015. № 8(78). С. 60-72.

Карабанов А.В., Федотова Е.Ю., Иллариошкин С.Н. Ра-загилин в начальной стадии болезни Паркинсона: результаты сравнительного контролируемого исследования эффективности препарата в параллельных группах больных. Нервные болезни. 2012. № 3. С. 38-44.

Котвіцька А.А., Прокопенко О.С. Вивчення показників поширеності та захворюваності на хворобу Паркінсона у різних регіонах світу. Соціальна фармація в охороні здоров’я. 2017. Т. 3. № 4. С. 76-82. doi: org/10.24959/sphhcj.17.93

Нодель М.Р. Стратегия и тактика терапии ранних стадий болезни Паркинсона. Неврологический журнал. 2016. № 3. С. 173-181.

Пономарев В.В., Бойко А.В., Ионова О.А. Лабораторные биомаркеры ранней диагностики болезни Паркинсона. Міжнародний неврологічний журнал. 2016. № 3(81).

С. 17-22.

Рекомендації щодо діагностики та лікування хвороби Паркінсона; за редакцією д-ра мед. наук, професора І.М. Карабань. Київ: ТОВ «Медичний журнал «Нейроньюс», 2017. 84 с.

A controlled trial of rasagaline in early Parkinson disease: the TEMPO Study / Parkinson Study Group. Arch. Neurol. 2002. Vol. 59. № 12. P. 1937-1943.

Alves G., Forsaa E.B., Pedersen K.F. et al. Epidemiology of Parkinsons disease. 2008. Vol. 255 (Suppl. 5). P. 18-32.

Bar-Am O., Amit T., Youdim M.B. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively,

exert neuroprotective properties in vitro. J. Neurochem. 2007. Vol. 103. P. 500-508.

Braak H., Tredici K.D., Rub U. et al. Staging of brain patho­logy related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003. Vol. 24. № 2. P. 197-211.

Brooks D.J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease. J. Neurol. 2000. Vol. 247. Suppl. 2. P. II/11-II/18.

Cacabelos R., Angelini S. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. International Journal of Molecular Sciences. 2017. Vol. 18(3). P. 551. doi:10.3390/ijms18030551.

Cereda E., Cilia R., Canesi M. et al. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J. Neurol. 2017. Jun. 264(6). P. 1254-1263. doi: 10.1007/s00415-017-8523-y.

Chang Y., Wang L.B., Li D. et al. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann. Med. 2017. Aug. 49(5). P. 421-434. doi: 10.1080/07853890.2017.1293285.

Edmondson D.E., Binda С. Monoamine Oxidases. Subcell. Biochem. 2018. Vol. 87. P. 117-139. doi: 10.1007/978-981-10-7757-9_5.

Ferreira J.J., Katzenschlagerb R., Bloemc B.R. et al. Summary of the recommendations of the efnS/MDS-eS review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013. Vol. 20(1). P. 5-15.

Frakey L.L., Friedman J.H. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson’s Disease Without Dementia. J. Neuropsychiatry Clin. Neurosci. 2017. Winter, 29(1). P. 22-25. doi: 10.1176/appi.neuropsych.15050118. URL:

Hattori N., Takeda A., Takeda S. et al. Rasagiline monotherapy in early Parkinson’s disease: A phase 3, randomized study in Japan. Parkinsonism and Related Disorders. URL: https//

Kang S.S., Zhang Z., Liu X. et al. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease. Proc. Natl Acad. Sci USA. 2017. Vol. 114(40). P. 10773-10778. doi: 10.1073/pnas.1713969114.

Nayak L., Henchcliffe С. Rasagiline in treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2008. Feb. 4(1). P. 23-32.

Lin X., Cook T.J., Zabetian C.P. et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci. Rep. 2012. № 2(7). Р. 954-967.

Mandel S., Weinreb O., Amit T. et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Rev. 2005. Vol. 48. P. 379-387.

Morgan J., Currie L., Harrison M. et al. Mortality in Levodopa-Treated Parkinson’s Disease. Parkinson’s Disease. 2014. P. 1-8. URL:

Olanow C.W., Hauser R.A., Jankovic J. et al. A rando-mized, double-blind, placebocontrolled, delayed start study to assess rasagaline as a disease modifying therapy in Parkinson’s disease (The ADAGIO Study): rationalc, design, and baseline characteristics. Mov. Disord. 2008. Vol. 23. № 15. P. 2194-2201.

Oldfield V., Keating G.M., Perry C.M. Rasagiline: a review of its use in the management of Parkinson’s disease. Drugs. 2007. Vol. 67(12). P. 1725-1747.

Panisset M., Stril L., Bélanger M. et al. Open-Label Study of Sleep Disturbances in Patients with Parkinson’s Disease Treated with Rasagiline. Can. J. Neurol. Sci. 2016. Nov. 43(6). P. 809-814.

Rascol O., Brooks D.J., Melamed Е. et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005. Vol. 365. P. 947-954.

Schapira A.H., Jenner Р. Etiology and pathogenesis of Parkinson’s disease. Movement Disorders Journal. 2011. Vol. 26(6). P. 1049-1055. doi: 10.1002/mds.23732

Schrempf W., Fauser M., Wienecke М. et al. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson’s disease: a double-blind, baseline-controlled trial. Eur. J. Neurol. 2018. Apr. 25(4). P. 672-679. doi: 10.1111/ene.13567.

Stocchi F., Fossati C., Torti М. Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin. Pharmacother. 2015. Vol. 16(14). P. 2231-2241. doi: 10.1517/14656566.2015.1086748.

World Health Organization. Neurological disorders: public health challenges [Electronic resourse]. WHO Library Cataloguing-in-Publication Data, 2006. URL:

Wilkinson J.R. et al. Neurology. 2008. Vol. 70. Suppl. 1. Р. 58.

Youdim M.B.H. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J. Neural. Transm. (Vienna). 2018. Nov. 125(11). P. 1719-1733. doi: 10.1007/s00702-018-1942-9.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта